Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban

被引:38
|
作者
Winkle, Roger A. [1 ,2 ]
Mead, R. Hardwin [1 ,2 ]
Engel, Gregory [1 ,2 ]
Kong, Melissa H. [1 ,2 ]
Patrawala, Rob A. [1 ,2 ]
机构
[1] Silicon Valley Cardiol, East Palo Alto, CA 94303 USA
[2] Sequoia Hosp, Redwood City, CA USA
来源
EUROPACE | 2014年 / 16卷 / 10期
关键词
Atrial fibrillation; Ablation; Dabigatran; Rivaroxaban; Warfarin; Anticoagulation; INTERNATIONAL NORMALIZED RATIO; CATHETER ABLATION; RADIOFREQUENCY ABLATION; MANAGEMENT; SAFETY; COMPLICATIONS; METAANALYSIS; STRATEGIES; EFFICACY; IMPROVES;
D O I
10.1093/europace/euu196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Atrial fibrillation ablation requires peri-procedural oral anticoagulation (OAC) to prevent thromboembolic events. There are several options for OAC. We evaluate peri-procedural AF ablation complications using a variety of periprocedural OACs. Methods and results We examined peri-procedural OAC and groin, bleeding, and thromboembolic complications for 2334 consecutive AF ablations using open irrigated-tip radiofrequency (RF) catheters. Pre-ablation OAC was warfarin in 1113 (47.7%), dabigatran 426 (18.3%), rivaroxaban 187 (8.0%), aspirin 472 (20.2%), and none 136 (5.8%). Oral anticoagulation was always interrupted and intraprocedural anticoagulation was unfractionated heparin (activated clotting time, ACT = 237 +/- 26 s). Pre-and post-OAC drugs were the same for 1591 (68.2%) and were different for 743 (31.8%). Following ablation, 693 (29.7%) were treated with dabigatran and 291 (12.5%) were treated with rivaroxaban. There were no problems changing from one OAC pre-ablation to another post-ablation. Complications included 12 (0.51%) pericardial tamponades [no differences for dabigatran (P = 0.457) or rivaroxaban (P = 0.163) compared with warfarin], 12 (0.51%) groin complications [no differences for rivaroxaban (P = 0.709) and fewer for dabigatran (P = 0.041) compared with warfarin]. Only 5 of 2334 (0.21%) required blood transfusions. There were two strokes (0.086%) and no transient ischaemic attacks (TIAs) in the first 48 h post-ablation. Three additional strokes (0.13%), and two TIAs (0.086%) occurred from 48 h to 30 days. Only one stroke had a residual deficit. Compared with warfarin, the neurologic event rate was not different for dabigatran (P = 0.684) or rivaroxaban (P = 0.612). Conclusion Using interrupted OAC, low target intraprocedural ACT, and irrigated-tip RF, the rate of peri-procedural groin, haemorrhagic, and thromboembolic complications was extremely low. There were only minimal differences between OACs. Low-risk patients may remain on aspirin/no OAC pre-ablation. There are no problems changing from one OAC pre-ablation to another post-ablation.
引用
收藏
页码:1443 / 1449
页数:7
相关论文
共 50 条
  • [1] Periprocedural Interrupted Oral Anticoagulation for Atrial Fibrillation Ablation: "Mixing and Matching" Aspirin, Warfarin, Dabigatran and Rivaroxaban
    Winkle, Roger A.
    Mead, R. Hardwin
    Engel, Gregory
    Kong, Melissa H.
    Patrawala, Rob A.
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (05) : 566 - 567
  • [2] Dabigatran is as Safe as Warfarin for Peri-Procedural Anticoagulation in Atrial Fibrillation Ablation: A Meta-Analysis
    Swaminathan, Paari Dominic
    Prasath, Arun
    Makki, Nader
    Kalamkar, Prachi
    Bhatt, Paras
    Clancy, Jude
    [J]. CIRCULATION, 2013, 128 (22)
  • [3] Uninterrupted Novel Oral Anticoagulants and Warfarin Use for Peri-procedural Anticoagulation during Atrial Fibrillation Ablation
    Kanmanthareddy, Arun K.
    Buddam, Avanija R.
    Reddy, Madhu
    Alla, Venkata M.
    Hunter, Claire
    Lakkireddy, Dhanunjaya
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B82 - B83
  • [4] Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
    Bin Abdulhak, Aref A.
    Khan, Abdur Rahman
    Tleyjeh, Imad M.
    Spertus, John A.
    Sanders, Susan U.
    Steigerwalt, Kristy E.
    Garbati, Musa A.
    Bahmaid, Reem A.
    Wimmer, Alan P.
    [J]. EUROPACE, 2013, 15 (10): : 1412 - 1420
  • [5] Peri-procedural Anticoagulation in Catheter Ablation Atrial Fibrillation: A Review
    Vrachatis, Dimitrios A.
    Giannopoulos, Georgios
    Kossyvakis, Charalambos
    Panagopoulou, Vasiliki
    Vavuranakis, Manolis
    Papaioannou, Theodore G.
    Pagoni, Stamatina
    Pyrgakis, Vlasios N.
    Cleman, Michael W.
    Deftereos, Spyridon G.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (09) : 1334 - 1345
  • [6] Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation
    Vazquez, Sara R.
    Johnson, Stacy A.
    Rondina, Matthew T.
    [J]. THROMBOSIS RESEARCH, 2010, 126 (02) : E69 - E77
  • [7] The Peri-procedural Use of Dabigatran in Patients Undergoing Left Atrial Ablation for Atrial Fibrillation
    Somani, Riyaz
    Mohajer, Kiarash
    Haley, Charlotte
    Simpson, Christopher S.
    Abdollah, Hoshiar
    Baranchuk, Adrian
    Redfearn, Damian P.
    Michael, Kevin
    [J]. CARDIOVASCULAR THERAPEUTICS, 2014, 32 (05) : 198 - 201
  • [8] COMPARISON OF ATRIAL FIBRILLATION ABLATION BLEEDING AND THROMBOTIC COMPLICATIONS WITH DABIGATRAN, RIVAROXABAN AND WARFARIN
    Bernard, Michael
    Brabham, William
    Netzler, Peter
    Rowley, Christopher
    Gold, Michael
    Leman, Robert
    Sturdivant, John
    Wharton, J. Marcus
    Cuoco, Frank
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E276 - E276
  • [9] Comparison of Atrial Fibrillation Ablation Bleeding and Thrombotic Complications with Dabigatran, Rivaroxaban and Warfarin
    Bernard, Michael
    Brabham, William
    Rowley, Chris
    Netzler, Peter
    Leman, Robert
    Sturdivant, J. Lacy
    Gold, Michael
    Wharton, J. Marcus
    Cuoco, Frank
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (05) : 572 - 572
  • [10] Dabigatran versus Warfarin Therapy for Uninterrupted Oral Anticoagulation During Atrial Fibrillation Ablation
    Maddox, William
    Kay, G. Neal
    Yamada, Takumi
    Osorio, Jose
    Doppalapudi, Harish
    Plumb, Vance J.
    Gunter, Alicia
    Mcelderry, H. Thomas
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2013, 24 (08) : 861 - 865